Definition
There are more than 100 viruses in the herpesvirus family, which is divided into three subfamilies, alpha, beta, and gamma, based on the genome structure and biological behavior of the viruses. Epstein-Barr virus (EBV) is one of the eight herpesviruses currently known to infect humans and is a member of the gammaherpesvirus subfamily, genus Lymphocryptovirus. Like all herpesviruses it can establish latent infections and persist for the lifetime of the host. In some individuals it behaves more as a commensal than a pathogen, while in others it can cause significant and even life-threatening disease.
Introduction
All viruses are problematic for those who are infected with the human immunodeficiency virus (HIV), but the herpesviruses, which are often carried by the vast majority of individuals worldwide and are typically fairly well controlled by a functioning immune system, pose a particular concern. EBV, like its fellow oncogenic gammaherpesvirus, Kaposi’s sarcoma-associated...
References
Appleby P, Beral V, Newton R, Reeves G. International Collaboration on HIV and Cancer: highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92:1823.
Borza CM, Hutt-Fletcher LM. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med. 2002;8:594–9.
Chesnokova LS, Nishimura S, Hutt-Fletcher L. Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral proteins gHgL to integrins αvβ6 or αvβ8. Proc Natl Acad Sci U S A. 2009;106:20464–9.
Cohen JI. Clinical aspects of Epstein-Barr virus infection. In: Robertson ES, editor. Epstein-Barr virus. Norfolk: Caister Academic Press; 2005. p. 35–54.
Connolly SA, Jackson JO, Jardetzky TS, Longnecker R. Fusing structure and function: a structural view of the herpesvirus entry machinery. Nat Rev Microbiol. 2011;9:369–81.
Frappier L. Role of EBNA1 in NPC tumourigenesis. Semin Cancer Biol. 2012;22:154–61.
Gromminger S, Mautner J, Bornkamm GW. Burkitt lymphoma: the role of Epstein-Barr virus revisited. Br J Haematol. 2012;156:719–29.
Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to virus infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 2007;25:587–617.
Hoshino Y, Katano H, Zou P, Hohman P, Marques A, Tyring SK, Follman D, Cohen JI. Long term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers. J Virol. 2009;83:11857–61.
Hutt-Fletcher LM. Epstein-Barr virus entry. J Virol. 2007;81:7825–32.
Imai S, Nishikawa J, Takada K. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol. 1998;72:4371–8.
Jiang R, Scott RS, Hutt-Fletcher LM. Epstein-Barr virus shed in saliva is high in B cell tropic gp42. J Virol. 2006;80:7281–3.
Kieff ED, Rickinson AB. Epstein-Barr virus and its replication. In: Knipe DM, Howley PM, editors. Fields virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 2603–54.
Lo KW, Chung GT, To KF. Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin Cancer Biol. 2012;22:79–86.
Long HM, Taylor GS, Rickinson A. Immune defence against EBV and EBV-associated disease. Curr Opin Immunol. 2011;23:258–64.
Magrath I. Epidemiology: clues to the pathogenesis of Burkitt’s lymphoma. Brit J Haematol. 2012;156:744–56.
Mettenleiter TC. Herpesvirus assembly and egress. J Virol. 2002;76:1537–47.
Nava VE, Jaffe ES. The pathology of NK-cell lymphomas and leukemias. Adv Anat Pathol. 2005;12:27–34.
Nokta M. Oral manifestations of AIDS. Curr HIV/AIDS Rep. 2008;5:5–12.
Odumade OA, Hogquist KA, Balfour Jr HH. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev. 2011;24:193–209.
Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, editors. Fields virology, vol. 2. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 2655–700.
Sashihara J, Hoshino Y, Bowman JJ, Krogmann T, Burbelo PD, Coffield VM, Kamrud K, Cohen JI. Soluble rhesus lymphocryptovirus gp30 protects against infection and reduces viral loads in animals that become infected with virus after challenge. PLoS Pathog. 2011;7:e1002308.
Sokal EM, Hoppenbrouwers K, Vandemeulen C, Moutchen M, Leonard P, Moreels M, Haumont M, Smets F, Denis M. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis. 2007;196:1749–53.
Thorley-Lawson DA, Gross A. Persistence of Epstein-Barr virus and the origins of associated lymphomas. New Engl J Med. 2004;350:1328–37.
Zeng Y, Zhang LG, Wu YC, Huang YS, Huang NQ, Li JY, Wang B, Jiang MK, Fang Z, Meng NN. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer. 1985;36:545–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this entry
Cite this entry
Hutt-Fletcher, L. (2013). Epstein-Barr Virus (EBV). In: Hope, T., Stevenson, M., Richman, D. (eds) Encyclopedia of AIDS. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9610-6_11-1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9610-6_11-1
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Online ISBN: 978-1-4614-9610-6
eBook Packages: Springer Reference MedicineReference Module Medicine